Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population

Gene

Volumn 568, Issue 1, 2015, Pages 85-88

  D'Amico, Mario ^a   Pasta, Francesca ^b   Pasta, Linda ^b,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Department of Surgery   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Alcoholic cirrhosis; Cirrhosis; Cryptogenic liver cirrhosis; Genetic mutation; HBV; HCV; Liver; Liver fibrosis; Methylenetetrahydrofolate reductase; MTHFR; MTHFR C677T; PAI 1; Plasminogen activator inhibitor type 1; Portal vein thrombosis; Prothrombin 20210A; Prothrombin gene; Thrombophilia; V Leiden 506Q

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CAUCASIAN; ESOPHAGUS VARICES; FEMALE; GENE; GENETIC PARAMETERS; GENETIC RISK; GENOTYPE; HARDY WEINBERG EQUILIBRIUM; HEPATITIS B; HEPATITIS C; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MTHFR 677TT GENE; PAI 1 4G 4G GENE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPLEEN DISEASE; SPLENIC VEIN THROMBOSIS; STATISTICAL SIGNIFICANCE; THROMBOPHILIA; VEIN THROMBOSIS; ADVERSE EFFECTS; DRINKING BEHAVIOR; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LIVER CIRRHOSIS; PATHOLOGY; PORTAL VEIN; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ALCOHOL DRINKING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PORTAL VEIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84930864691     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.05.034     Document Type: Article

References (28)

1. 2-way contingency table analysis http://statpages.org/ctab2x2.html.
2. AbdulHameed M.D., Tawa G.J., Kumar K., Ippolito D.L., Lewis J.A., Stallings J.D., et al. Systems level analysis and identification of pathways and networks associated with liver fibrosis. PLoS One 2014, 9:e112193.
3. Adinolfi L.E., Ingrosso D., Cesaro G., Cimmino A., D'Antò M., Capasso R., et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, 41:995-1003.
4. Anstee Q.M., Dhar A., Thursz M.R. The role of hypercoagulability in liver fibrogenesis. Clin. Res. Hepatol. Gastroenterol. 2011, 35:526-533.
5. Assy N., Bekirov I., Mejritsky Y., Solomon L., Szvalb S., Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J. Gastroenterol. 2005, 11:5834-5839.
6. Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype, a risk factor for thrombosis in vessel of internal organs. Am. J. Hematol. 2002, 71:89-93.
7. Bosch J., Abraldes J.G., Fernández M., García-Pagán J.C. Hepatic endothelial dysfunction and abnormal angiogenesis, new targets in the treatment of portal hypertension. J. Hepatol. 2010, 53:558-567.
8. D'Amico M., Pasta L., Sammarco P. MTHFR C677TT, PAI-1 4G-4G, V Leiden Q506, and prothrombin 20210A in hepatocellular carcinoma with and without portal vein thrombosis. J. Thromb. Thrombolysis 2009, 28:70-73.
9. Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology 2014, 10.1002/hep.27343.
10. Gialluisi A., Incollu S., Pippucci T., Lepori M.B., Zappu A., Loudianos G., Romeo G. The homozygosity index (HI) approach reveals high allele frequency for Wilson disease in the Sardinian population. Eur. J. Hum. Genet. 2013, 21:1308-1311. 10.1038/ejhg.2013.43.
11. Hosmer, D.W., Lemeshow, S. (Eds.), 1989. Applied Logistic Regression 1989, John Wiley & Sons, New York.
12. Janssen H.L., Meinardi J.R., Vleggaar F.P., van Uum S.H., Haagsma E.B., van Der Meer F.J., et al. Factor V Leiden 506Q mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis, results of a case-control study. Blood 2000, 96:2364-2368.
13. Lee J.H., Jang E.J., Seo H.L., Ku S.K., Lee J.R., Shin S.S., Park S.D., Kim S.C., Kim Y.W. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through THRGF- β/Smad signaling pathway. Chem. Biol. Interact. 2014, 16:58-67.
14. Logistic Regression in Logistic Regression Calculating Page by John C. Pezzullo, instruction modifications by Kevin M.Sullivan, 2015. Version 05.07.20. statpages.org/logistic.html.
15. Maharshak N., Halfon P., Deutsch V., Peretz H., Berliner S., Fishman S., et al. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J. Gastroenterol. 2011, 17:5007-5013.
16. Parikh S., Shah R., Kapoor P. Portal vein thrombosis. Am. J. Med. 2010, 123:111-119.
17. Pasta L., Marrone C., D'Amico M., Verdone R., Rizzo A., Sammarco P., et al. MTHFR 677TT homozygous as risk factor for complications after OLT for cryptogenic cirrhosis. Clin. Transplant. 2006, 20:796-798.
18. Pasta L., Marrone C., D'amico M., Virdone R., D'amico G., Sammarco P., et al. MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. Liver Int. 2006, 26:269-270.
19. Patnaik M., Dlott J.S., Fontaine R.N., Subbiah M.T., Hessner M.J., Joyner K.A., et al. Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. J. Mol. Diagn. 2004, 6:137-144. (17).
20. Perez-Pujol S., Aras O., Escolar G. Factor V leiden and inflammation. Thrombosis 2012, 2012:594986. 10.1155/2012/594986.
21. Primignani M., Mannucci P.M. The role of thrombophilia in splanchnic vein thrombosis. Semin. Liver Dis. 2008, 28:293-301.
22. Primignani M., Martinelli I., Bucciarelli P., Battaglioli T., Reati R., Fabris F., et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005, 4:603-608.
23. Rodriguez S., Gaunt T.R., Day I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 2008, 169:505-514.
24. Sample Size Calculator Determines the minimum number of subjects for adequate study power 2014, http://clincalc.com/Stats/Power.aspx.
25. Saugel B., Lee M., Feichtinger S., Hapfelmeier A., Schmid R.M., Siveke J.T. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J. Thromb. Thrombolysis Aug 14 2014, [Epub ahead of print].
26. Toniutto P., Fabris C., Falleti E., Cussigh A., Fontanini E., Bitetto D., Fornasiere E., Minisini R., De Feo T., Marangoni F., Pirisi M., et al. Methylenetetrahydrofolate reductase C677Tpolymorphism and liver fibrosis progression in patients with recurrent hepatitis C. Liver Int. 2008, 28:257-263.
27. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Bonovas S., Kopterides P., Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb. Res. 2008, 122:736-742.
28. Zhang L.P., Takahara T., Yata Y., Furui K., Jin B., Kawada N., et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J. Hepatol. 1999, 31:703-711.